Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Feb 18, 2026 06:59AM
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12 million Dec 1, 2025 07:07AM
Q32 Bio Sells Complement Inhibitor ADX-097 Dec 1, 2025 07:00AM
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update Nov 13, 2025 06:59AM
Q32 Bio completes enrollment in phase 2a trial for alopecia areata drug Oct 21, 2025 06:59AM


Oct 21, 2025 06:59AM Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Aug 28, 2025 06:59AM Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 6, 2025 06:59AM Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 25, 2025 06:59AM Q32 Bio (QTTB) Appoints Adrien Sipos as Interim Chief Medical Officer
Jun 25, 2025 06:59AM Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
May 8, 2025 06:59AM Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 30, 2025 07:00AM Q32 Bio (QTTB) Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Apr 30, 2025 06:59AM Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Apr 16, 2025 07:02AM Q32 Bio (QTTB) Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Apr 16, 2025 06:59AM Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Mar 11, 2025 06:59AM Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Mar 8, 2025 11:00AM Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Feb 28, 2025 09:00AM Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Feb 26, 2025 06:59AM Q32 Bio to Participate in Upcoming March Investor Conferences
Feb 10, 2025 04:05PM Q32 Bio (QTTB) Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Feb 10, 2025 04:05PM Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Feb 4, 2025 04:05PM Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Dec 10, 2024 04:21PM Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activity
Dec 10, 2024 04:05PM Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
Nov 7, 2024 06:59AM Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 5, 2024 06:59AM Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Oct 14, 2024 06:59AM Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Aug 29, 2024 06:59AM Q32 Bio to Participate in Upcoming September Investor Conferences
Aug 8, 2024 06:59AM Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 9, 2024 06:59AM Q32 Bio (QTTB) Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Jul 9, 2024 06:59AM Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Jul 1, 2024 06:59AM Q32 Bio (QTTB) to Join Russell 3000
Jul 1, 2024 06:59AM Q32 Bio Joins Russell 3000® Index